AbbVie Inc. announced its agreement to acquire Capstan Therapeutics, a biotechnology company specializing in in vivo engineering of cells through RNA delivery using targeted lipid nanoparticles (tLNPs). AbbVie will pay up to $2.1 billion in cash for the acquisition. This transaction includes Capstan's lead asset, CPTX2309, an anti-CD19 CAR-T therapy candidate currently in Phase 1, aimed at treating B cell-mediated autoimmune diseases. The acquisition also involves Capstan's proprietary tLNP platform technology, which is designed to deliver RNA payloads such as mRNA to specific cell types in vivo. Laura Shawver, Ph.D., president and CEO of Capstan, highlighted the potential of in vivo CAR-T as a new treatment modality that combines the transformative power of cell therapy with the accessibility of an off-the-shelf biologic. Shawver emphasized the shared mission with AbbVie to advance these innovative therapies to patients in need.